Outlook Therapeutics, Inc. (OTLK)
0.6587
0.00 (0.00%)
USD |
NASDAQ |
Jan 05, 09:31
Outlook Therapeutics Research and Development Expense (Quarterly): 7.135M for June 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.99M |
| Neogen Corp. | 5.125M |
| NovaBay Pharmaceuticals, Inc. | -- |
| Palatin Technologies, Inc. | 2.526M |
| Theriva Biologics, Inc. | 2.551M |